{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:24:05Z","timestamp":1791228245548,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Urogynecol J"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s00192-024-06028-3","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T08:56:55Z","timestamp":1737449815000},"page":"469-474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Onabotulinum Toxin A-Led Urinary Tract Infections\u2014Should we Safeguard? A Randomized Controlled Trial"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3612-9867","authenticated-orcid":false,"given":"Anastasiya","family":"Holubyeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaythi","family":"Khin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun","family":"Adair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Wasenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Dhariwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Caraballo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svjetlana","family":"Lozo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Rutledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Botros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"issue":"3","key":"6028_CR1","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.juro.2016.03.146","volume":"196","author":"VW Nitti","year":"2016","unstructured":"Nitti VW, Ginsberg D, Sievert KD, Sussman D, Radomski S, Sand P, et al. Durable efficacy and safety of long-term onabotulinumtoxinA treatment in patients with overactive bladder syndrome: final results of a 3.5-year study. J Urol. 2016;196(3):791\u2013800.","journal-title":"J Urol"},{"issue":"10","key":"6028_CR2","doi-asserted-by":"publisher","first-page":"1619","DOI":"10.1007\/s11255-015-1100-3","volume":"47","author":"H Hashim","year":"2015","unstructured":"Hashim H, Beusterien K, Bridges JF, Amos K, Cardozo L. Patient preferences for treating refractory overactive bladder in the UK. Int Urol Nephrol. 2015;47(10):1619\u201327.","journal-title":"Int Urol Nephrol"},{"issue":"10","key":"6028_CR3","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/ijcp.12443","volume":"68","author":"KD Sievert","year":"2014","unstructured":"Sievert KD, Chapple C, Herschorn S, Joshi M, Zhou J, Nardo C, Nitti VW. OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. Int J Clin Pract. 2014;68(10):1246\u201356.","journal-title":"Int J Clin Pract"},{"issue":"3","key":"6028_CR4","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3390\/toxins8030075","volume":"8","author":"YC Kuo","year":"2016","unstructured":"Kuo YC, Kuo HC. Adverse events of intravesical onabotulinumtoxinA injection between patients with overactive bladder and interstitial cystitis-different mechanisms of action of Botox on bladder dysfunction? Toxins (Basel). 2016;8(3):75.","journal-title":"Toxins (Basel)"},{"issue":"19","key":"6028_CR5","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1208872","volume":"367","author":"AG Visco","year":"2012","unstructured":"Visco AG, Brubaker L, Richter HE, Nygaard I, Paraiso MF, Menefee SA, Schaffer J, Lowder J, Khandwala S, Sirls L, Spino C, Nolen TL, Wallace D, Meikle SF, Pelvic Floor Disorders Network. Anticholinergic therapy vs. onabotulinumtoxinA for urgency urinary incontinence. N Engl J Med. 2012;367(19):1803\u201313.","journal-title":"N Engl J Med"},{"issue":"13","key":"6028_CR6","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1001\/jama.2016.14617","volume":"316","author":"CL Amundsen","year":"2016","unstructured":"Amundsen CL, Richter HE, Menefee SA, Komesu YM, Arya LA, Gregory WT, Myers DL, Zyczynski HM, Vasavada S, Nolen TL, Wallace D, Meikle SF. OnabotulinumtoxinA vs sacral neuromodulation on refractory urgency urinary incontinence in women: a randomized clinical trial. JAMA. 2016;316(13):1366\u201374.","journal-title":"JAMA"},{"issue":"5","key":"6028_CR7","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s00192-018-3721-4","volume":"30","author":"J Houman","year":"2019","unstructured":"Houman J, Moradzadeh A, Patel DN, Asanad K, Anger JT, Eilber KS. What is the ideal antibiotic prophylaxis for intravesically administered Botox injection? A comparison of two different regimens. Int Urogynecol J. 2019;30(5):701\u20134.","journal-title":"Int Urogynecol J"},{"key":"6028_CR8","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/JU.0000000000000509","volume":"203","author":"DJ Lightner","year":"2020","unstructured":"Lightner DJ, Wymer K, Sanchez J, Kavoussi L. Best practice statement on urologic procedures and antimicrobial prophylaxis. J Urol. 2020;203:351.","journal-title":"J Urol"},{"key":"6028_CR9","unstructured":"Allergan. BOTOX Cosmetic (onabotulinumtoxinA) for injection, for intramuscular use. Accessed 1 October 2019."},{"issue":"18","key":"6028_CR10","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1016\/j.jmb.2019.06.033","volume":"431","author":"TA Wencewicz","year":"2019","unstructured":"Wencewicz TA. Crossroads of antibiotic resistance and biosynthesis. J Mol Biol. 2019;431(18):3370\u201399.","journal-title":"J Mol Biol"},{"issue":"12","key":"6028_CR11","doi-asserted-by":"publisher","first-page":"e51034","DOI":"10.15252\/embr.202051034","volume":"21","author":"M Huemer","year":"2020","unstructured":"Huemer M, Mairpady Shambat S, Brugger SD, Zinkernagel AS. Antibiotic resistance and persistence\u2014implications for human health and treatment perspectives. EMBO Rep. 2020;21(12):e51034.","journal-title":"EMBO Rep"},{"issue":"3","key":"6028_CR12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s00192-021-04691-4","volume":"33","author":"SE Eckhardt","year":"2022","unstructured":"Eckhardt SE, Takashima Y, Handler SJ, Tenggardjaja C, Yazdany T. Antibiotic regimen and route of administration do not alter rates of urinary tract infection after intravesical botulinum toxin injection for overactive bladder. Int Urogynecol J. 2022;33(3):703\u20139.","journal-title":"Int Urogynecol J"},{"key":"6028_CR13","unstructured":"ICS, International Continence Society. Urinary retention. ICS. https:\/\/www.ics.org\/committees\/standardisation\/terminologydiscussions\/urinaryretention.\u00a0Accessed Sept 2024"},{"issue":"2","key":"6028_CR14","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","volume":"64","author":"C Chapple","year":"2013","unstructured":"Chapple C, Sievert KD, MacDiarmid S, Khullar V, Radziszewski P, Nardo C, Thompson C, Zhou J, Haag-Molkenteller C. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2013;64(2):249\u201356.","journal-title":"Eur Urol"},{"issue":"3","key":"6028_CR15","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/SPV.0000000000001466","volume":"30","author":"CW Heuer","year":"2024","unstructured":"Heuer CW, Gisseman JD, Vaccaro CM, Olsen CH, Galgano AC, Dengler KL. Antibiotics for UTI prevention after intradetrusor onabotulinumtoxinA injections. Urogynecology (Phila). 2024;30(3):272\u20139.","journal-title":"Urogynecology (Phila)"},{"issue":"1","key":"6028_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s00192-023-05665-4","volume":"35","author":"FW Getaneh","year":"2024","unstructured":"Getaneh FW, Simhal R, Sholklapper T, Melvin E, Dorris CS, Chou J, Richter LA, Dieter A. Antibiotic prophylaxis for onabotulinum toxin A injections: systematic review and meta-analysis. Int Urogynecol J. 2024;35(1):19\u201329. https:\/\/doi.org\/10.1007\/s00192-023-05665-4.","journal-title":"Int Urogynecol J"},{"issue":"4","key":"6028_CR17","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00003-20","volume":"34","author":"MC Goebel","year":"2021","unstructured":"Goebel MC, Trautner BW, Grigoryan L. The five Ds of outpatient antibiotic stewardship for urinary tract infections. Clin Microbiol Rev. 2021;34(4): e0000320. https:\/\/doi.org\/10.1128\/CMR.00003-20.","journal-title":"Clin Microbiol Rev"}],"container-title":["International Urogynecology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-024-06028-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00192-024-06028-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00192-024-06028-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T12:46:59Z","timestamp":1740401219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00192-024-06028-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["6028"],"URL":"https:\/\/doi.org\/10.1007\/s00192-024-06028-3","relation":{},"ISSN":["0937-3462","1433-3023"],"issn-type":[{"value":"0937-3462","type":"print"},{"value":"1433-3023","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"3 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}